950210 — Prestige Biopharma Share Price
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- $0.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.01 | ||
| Price to Tang. Book | 9.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3,039.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.27% | ||
| Return on Equity | -7.27% | ||
| Operating Margin | -7489.81% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.84 | n/a | n/a | n/a | 0.12 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 13th, 2015
- Public Since
- February 5th, 2021
- No. of Shareholders
- 40,726
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 72,115,386
- Address
- 21 Biopolis Road, 138567
- Web
- https://www.prestigebiopharma.com/
- Phone
- +65 69246535
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 950210
Similar to 950210
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Prestige Biopharma share price?
As of Today at 22:45 UTC, shares in Prestige Biopharma are trading at KR₩8,750. This share price information is delayed by 15 minutes.
How has the Prestige Biopharma share price performed this year?
Shares in Prestige Biopharma last closed at KR₩8,750 and the price had moved by -8.08% over the past 365 days. In terms of relative price strength the Prestige Biopharma share price has underperformed the FTSE Developed Asia Pacific Index by -12.04% over the past year.
What are the analyst and broker recommendations for Prestige Biopharma?
The overall consensus recommendation for Prestige Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Prestige Biopharma dividend yield?
Prestige Biopharma does not currently pay a dividend.
Does Prestige Biopharma pay a dividend?
Prestige Biopharma does not currently pay a dividend.
When does Prestige Biopharma next pay dividends?
Prestige Biopharma does not currently pay a dividend.
How do I buy Prestige Biopharma shares?
To buy shares in Prestige Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prestige Biopharma?
As of the previous close price of KR₩8,750, shares in Prestige Biopharma had a market capitalisation of KR₩3tn.
Where are Prestige Biopharma shares listed?
Here are the trading details for Prestige Biopharma:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 950210
What kind of share is Prestige Biopharma?
Based on an overall assessment of its quality, value and momentum Prestige Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prestige Biopharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Prestige Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prestige Biopharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -5.42%.
As of the last closing price of KR₩8,750, shares in Prestige Biopharma were trading -5.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prestige Biopharma PE Ratio?
The Prestige Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,750.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prestige Biopharma?
We do not have data on Prestige Biopharma's directors